Blurbs

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY) and GlycoMimetics (GLYC)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DENTSPLY SIRONA (XRAYResearch Report) and GlycoMimetics (GLYCResearch Report) with bullish sentiments.

DENTSPLY SIRONA (XRAY)

In a report released today, Brandon Couillard from Jefferies maintained a Buy rating on DENTSPLY SIRONA, with a price target of $37.00. The company’s shares closed last Friday at $31.13, close to its 52-week low of $26.48.

Couillard has an average return of 4.0% when recommending DENTSPLY SIRONA.

According to TipRanks.com, Couillard is ranked #30 out of 8112 analysts.

DENTSPLY SIRONA has an analyst consensus of Moderate Buy, with a price target consensus of $34.67, a 10.9% upside from current levels. In a report issued on November 14, Morgan Stanley also maintained a Buy rating on the stock with a $39.00 price target.

See the top stocks recommended by analysts >>

GlycoMimetics (GLYC)

In a report issued on November 19, Roger Song from Jefferies maintained a Buy rating on GlycoMimetics, with a price target of $3.00. The company’s shares closed last Friday at $2.25, close to its 52-week high of $2.43.

According to TipRanks.com, Song has 0 stars on 0-5 stars ranking scale with an average return of -29.1% and a 21.8% success rate. Song covers the Healthcare sector, focusing on stocks such as Kinnate Biopharma, IGM Biosciences, and Altimmune.

GlycoMimetics has an analyst consensus of Moderate Buy, with a price target consensus of $8.00, a 281.0% upside from current levels. In a report issued on November 9, H.C. Wainwright also maintained a Buy rating on the stock with a $13.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on XRAY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More